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Abstract
Background: Achalasia is an infrequent primary motility disorder of the esophagus. Because of
uncertain etiology, treatment is only palliative and is directed at decreasing lower esophageal sphincter
pressure, improving esophageal emptying and relieving the symptoms of achalasia. Current treatment
options include pharmacological, endoscopic and surgical. We undertook a systematic literature review
of the management strategies currently available for achalasia.
Method: A Medline, PubMed and Cochrane database search was conducted using reference manager
11. Original articles and reviews published in the English literature on the management of achalasia
were reviewed. Emphasis was placed on articles published in the last ten years on randomized
controlled trials comparing the various forms of treatment.
Results: Esophageal manometry is the standard diagnostic evaluation for achalasia. Accurate diagnosis
can also be made based on clinical findings and barium esophagogram. Medical treatment with nitrates
or calcium channel blockers has variable results in alleviating the symptoms of achalasia but long-term
results are disappointing because of tolerance and side effects. Intrasphincteric injection of botulinum
toxin, pneumatic dilatation and surgical myotomy are variably effective at controlling the symptoms of
achalasia but each modality has specific strength and weaknesses which make their choice suitable in a
particular group of patients. While pneumatic dilatation is superior to botulinum toxin injection surgical
myotomy provides the best long-term control of symptoms in patients with achalasia.
Conclusion: Laparoscopic myotomy should be the initial treatment for most patients with achalasia.
Pneumatic dilatation is the most cost-effective alternative but its long-term efficacy is less than that of
surgical myotomy. Endoscopic botulinum toxin injection can be considered when other forms of
treatment are contraindicated.
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Résumé
Contexte: L’achalasie est une rare anomalie motrice de l’œsophage. En raison de son étiologie
incertaine, le traitement est seulement palliatif et vise la réduire la pression sphinctérienne du bas
œsophage, l’amélioration de la vidange et le soulagement des symptômes de l’achalasie. Les options
thérapeutiques courantes font appel aux moyens pharmacologiques, endoscopiques et chirurgicaux.
Nous avons effectué une revue systématique de la littérature relative aux stratégies thérapeutiques
actuellement disponibles pour l’achalasie.
Méthode: Une recherche sur Medline, Pubmed et Cochrane a été faite a l’aide du logiciel Reference
Manager 11. Les articles originaux et les rapports portant sur la prise en charge de l’achalasie et publiés
en anglaise ont été passés en revue. L’accent a été mis sur les articles publiés au cours des dix dernières
années et sur les essais contrôlés comparant les diverses formes de traitement.
Résultats: La manométrie œsophagienne est la méthode de diagnostic standard pour l’achalasie. Le
diagnostic peut être affiné sur la base des données cliniques et du transit œsophagien. Le traitement
médical avec les nitrates ou les inhibiteurs des canaux calciques donnent des résultats variables sur
l’amélioration des symptômes de l’achalasie, mais les résultats à long terme sont décevants en raison
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de la tolérance et des effets secondaires. L’injection intra sphinctérienne de toxine botulique, la
dilatation pneumatique et la myotomie chirurgicale ont une efficacité variable sur le contrôle des
symptômes d’achalasie. Chaque méthode a ses avantages et ses inconvénients ce qui rend leur choix
adapté pour un groupe donné de patients. Alors que la dilatation pneumatique est meilleure que
l’injection de toxine botulique, la myotomie chirurgicale donne le meilleur contrôle des symptômes
chez les patients ayant une achalasie.
Conclusion: La myotomie laparoscopique devrait être le traitement initial pour la plupart des patients
ayant une achalasie. La dilatation pneumatique est la moins onéreuse des alternatives mais son
efficacité a long terme est moindre que celle de la myotomie chirurgicale. L’injection endoscopique de
toxine botulique peut être envisagée lorsque les autres formes de traitement sont contre indiquées.
Mots clés: Achalasie, esophagomyotomie de Heller, dilatation pneumatique
Introduction
The original description of achalasia was first made in
1674 by Sir Thomas Willis when he used whalebone
to dilate the esophagus of a patient who was unable
to swallow because of failure of the lower
esophageal sphincter to relax.
1
Achalasia is a benign
idiopathic disorder caused by progressive neuronal
degeneration of the myenteric plexus of Auerbach.
2, 3
It is the commonest primary esophageal motility
disorder. The pathophysiology of the process
represents a selective loss of inhibitory nerves that
result in unopposed stimulation of the smooth
muscle fibers of the LES. The etiology of primary
achalasia remains controversial. Histological
examination of the esophagus in achalasia suggests
that the reduction in intramural ganglion cells may be
a secondary change probably due to inflammation
triggered by autoimmune mechanism or a chronic
degenerative process of the central or peripheral part
of the vagus nerve.
4
The primary lesion could also be
a severe myopathy of the smooth muscle cells.
4,5
Familial occurrence and association with class II HLA
antigens also suggest genetic predisposition.
6,7
A secondary form of achalasia is Chagas disease,
an infectious disease cause by the parasite
Trypanasoma Cruzi. It seen mainly in Central and
South America where an estimated 11 million people
are infected.
8
In developed countries the incidence of
achalasia is 1 in 100 000 individuals.
9
In sub-Saharan
Africa, 3 to 4 patients are seen per year.
10-12
Among
other esophageal diseases, achalasia is observed in
3.1% - 20% of cases and is second to
gastrooesophageal reflux (GER) as the commonest
functional esophageal disorder requiring surgical
therapy.
13,14
In developing countries the peak incidence is in
the third decade, a decade lower than in developed
countries.
10,13
Typically, patients present with long-
standing progressive dysphagia for both liquid and
solid. Regurgitation of undigested food is common
and may result in aspiration and recurrent
respiratory tract infection. Retrosternal pain is a
prominent feature and may result from GER.
15
More
commonly it results from food stagnation and
bacterial growth in the distal esophagus or
fermentation of retained food.
15,16
Weight loss is seen
in 68% of patients and may be severe.
17
In developed
countries manometric diagnosis is obtained before
therapeutic intervention.
18
The most important finding is aperistalsis of the
body of the esophagus in the distal smooth muscle
segment of the esophagus.
14,19
Other manometric
findings that are characteristic but not necessary for
the diagnosis of achalasia are failure or incomplete
relaxation of the LES with swallowing, sustained
hypertension of the LES and elevated intra
esophageal body pressure compared to pressure
within the stomach.
14,18,19
Barium swallow is an
important diagnostic tool in patients with symptoms
suggestive of achalasia. Fluoroscopy reveals
repetitive non-peristaltic contractions of the
esophagus.
14, 19
As the disease progress there is
continuous dilatation of the esophagus until it
become tortuous or even sigmoid in appearance




swallow and pH- metry are also used for objective
evaluation of outcome of treatment. Other diagnostic
evaluations include esophagogastroduodenoscopy,




show mediastinal widening, presence of air-fluid level
in the mid-esophagus, absence of gastric air bubble
and abnormal pulmonary markings due to chronic
aspiration (Figure 2). In our setting as in others with
limited facilities, diagnosis of achalasia is made to a
high degree of accuracy given the symptom complex
of long-standing dysphagia, regurgitation and weight
loss with barium swallow showing delayed emptying,
dilatation of esophageal body and the classic bird
beak deformity of the distal esophagus.
10-12
Modalities of Treatment
Since the early treatment of achalasia in the 17th
century, surgeons have made a significant
advancement in the treatment of this disease and the
resultant outcomes have improved. Because the
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etiology of achalasia is not known therapy is directed
at relieving dysphagia and preventing stasis related
complications by reducing the outflow resistance
caused by the dysfunctional LES so that force of
gravity would be enough to transport food into the
stomach. Medical treatment, botulinum toxin (BTox)
injection, pneumatic dilatation (PD) and surgical
myotomy are the modalities currently available to
achieve this goal.
Figure 1. Sigmoid shape esophagus in end-
stage achalasia
Figure 2. Chest x-ray of a patient with achalasia
Medical treatment
Calcium channel blockers and nitrates are the drugs
commonly used to treat achalasia.
22-24
Calcium
channel blockers inhibit cellular calcium uptake and
as calcium is necessary for contraction, relaxation
occurs. Nifedipine given at a dose of 20 mg reduces
the LES pressure by 30 to 40%.
24, 25
Nitric oxide is the
measure neurotransmitter release from the myentric
neurons that induces swallow and esophageal
distension induced LES relaxation.
22
Nitrate acts by
compensating for the decrease in the inhibitory
neurotransmitter.
22
Both nifedipine and isosorbide
dinitrate are given sublingually 30 to 60 minutes
before meals. These drugs have variable results in
alleviating the symptoms of achalasia with initial
improvement rate of 50 to 90%.
26
However, long
term use of these drugs is associated with tolerance
which severely decreases their effects over time.
25
Nifedipine has induced long term remission and even
normalization of physiology in a few patients.
26
Unfortunately the common side effects of
hypotension, headache and peripheral edema occur
in about 30% of patients taking calcium channel
blockers or nitrates and this limits their clinical
use.
14,22
Sildenafil has been considered for the
treatment of achalasia but because of significant side
effects its clinical use has been abandoned.
27
It
inhibits phosephodiasterase type 5, which prevent
the destruction of nitric oxide-stimulated cyclic
guanisine monophosphate.
22,27
This action leads to
decrease in the resting LES pressure in patients with
achalasia but to a lesser extent than nifedipine.
14
Medical treatment has limited efficacy in patients
with achalasia. It is recommended only to patients as
a bridge to more definitive treatment or to those in
whom other treatments are contraindicated.
14, 22
Endoscopic botulinum toxin injection
Botulinum toxin is a neuro toxin that causes
sustained inhibition of neurotransmitter release at
cholinergic terminals. The toxins specifically bind the
presynaptic membrane and enter the cystol of the




which is used for the treatment of achalasia cleaves
the SNAP-25 molecule of the presynaptic membrane,
thus blocking acetylcholine (ACH) release.
29,30
In the early nineties, Pasrich and colleagues
evaluated the usefulness of intrasphincteric injection
of BTox in achalasia patients.
31,32
The rationale was
that the selective loss of inhibitory nerves in
achalasia upset the excitatory cholinergic influences
on the LES.
29
Thus by blocking the release of ACH,
locally injected BTox might reduce the LES pressure
and improve passive esophageal emptying.
29,33
The
toxin is injected through a standard schelerotherapy
needle during an upper endoscopy performed under
conscious sedation.
34
Usually, 80 to 100 units of
BTox- A are injected in each quadrant of the LES in
0.5 to 1ml aliquots.
28
This improves the symptoms of
achalasia, decrease LES pressure, increase lower
esophageal aperture and improve esophageal
emptying.
31
The clinical effects of a single injection
are short lived with relapse in more than 50% within
6 months.
28
However, repeated injections may confer
clinical benefit in 70% to 90%.
32
In one report, 21% of
newly diagnosed achalasia patients were treated
with BTox as the initial modality of treatment with an
average duration of effect of 6 months.
33
This waning
of efficacy over time is may be related to
development of autoimmune response with
production of antibodies against BTox.
31
Predictors of
good response to BTox injection are age less than 50
years, vigorous achalasia, an initial clinical response
to BTox injection and decrease in LES pressure in
response to BTox injection.
22,35
Achalasia of esophagus: what’s the best treatment? Ahmed A.
Page | 144
Endoscopic injection of BTox is remarkably safe.
About 10% of patients develop chest or epigastric




confers beneficial effects on subsequent pneumatic
dilatation which is actually enhanced.
22, 31
However,
repeated injection of the toxin makes subsequent
surgical myotomy more difficult due to adhesions of
the muscular layers to mucosal plane with an
increased danger of mucosal perforation.
14, 33
Given
its safety profile, BTox injection may be given to
patients who are not candidates for PD or surgery




Historically, dilatation was the first attempt at
treatment of achalasia.1 The principle is to weaken
the LES by tearing its muscle fibers by generating
radial force from within the esophagus. In the past, a
variety of mercury filled buggies, hydrostatic dilators
and metallic devices were used with varying degree
of success. Modern dilators consist of expanding
balloons that forcefully dilate the LES. Pneumatic
dilatation is currently the most effective non- surgical
treatment of achalasia.
14,17
However variations exit as
to the type of dilators, fluoroscopic or endoscopic




performed in the endoscopy suite under conscious
sedation. Single dilatation with Rigiflex dilator
resulted in 60% reduction in LES pressure and
resolution of symptoms in 70% of patients.
34
However, graduated dilatation results in a higher and
more durable clinical response.
37,38
A report from
Cleveland clinic showed that 41% of newly diagnosed
achalasia patients were initially treated with PD.
33
The clinical response was 86% in these patients with
improved esophageal emptying of 54%.
33
Pneumatic dilatation has the advantage of
achieving symptom relief while avoiding the risk
associated with invasive surgery. In addition, it can
be safely used when BTox injection or surgery have
failed.
22
The major problem of PD is the relatively
high mortality rate of 1 to 2%.
14,34
Gastrooesophageal
reflux is seen in 4% to 16% of patients.34 Perforation
occurs in 1% to 3% of patients many of who would
require emergency surgery.
38
The risk of perforation
is highest during the initial dilatation as oppose to
subsequent dilatation especially in patients with
vigorous achalasia.38 Predictors of good outcome of
PD include age above 50 years and more than 50%
reduction in LES pressure.
22,38
Overall, PD provides a
safe and effective way of achieving long-term control
of symptoms in patients with achalasia.
Surgical treatment
Historically, the treatment of achalasia by
cardiomyotomy was first designed by Gottstein in
1901.
39
However, in 1913 Heller acclaimed the
procedure by performing it abdominally on the
anterior and posterior esophageal walls.
40
Currently,
the universally accepted surgical treatment of
achalasia is the Heller myotomy, as modified by
Zaaijer.
41
Myotomy became the surgery of choice to
treat achalasia because of it simple technique on the
anterior wall of the esophagus accessed either by the
abdominal or thoracic root, by open or minimally
invasive surgery. In either case, the abdominal root is
preferred because the surgical set-up is easier and
anesthesia is simpler because single lung ventilation
is not required.
10
Postoperative management of the
patients is easier and they leave the hospital earlier.
The abdominal approach also provides opportunity




first described in 1991.
45
This procedure is associated
with significant decrease in dysphagia and low
complications rate. It provides symptoms relief in
about 90% of patients with more than 80% remaining
dysphagia free at 5 years.
18,46
However, the high cost
of this approach, access to reference centers, the
need of surgical skills that are not readily available
and surgeon learning curve are still an issue.
Recently, computer enhanced robotic telesurgery
provides further improvement over laparoscopic
Heller myotomy.
47
Open esophagomyotomy is associated with
relapse rate of less than 10% at 9 years and is




where facilities for laparoscopic approach are not
readily available Heller myotomy performed by
laparotomy represent a reliable and effective surgical
treatment for achalasia, with good to excellent
palliation of dysphagia in more than 80% of
patients.
11,12
The methods of assessing completeness
of division of the LES fibers during myotomy are intra
operative endoscopy and manometry.
14,48
Endoscopic
view allows precise identification of the
squamocolumnar junction and guides the proximal
and distal extent of the myotomy and also detects
perforations that can be repaired immediately.
14
Manometry on the other hand gives a more
functional assessment of the myotomy and can be
use to locate areas of residual high pressure zone.
48
The role of antireflux procedure following
esophagomyotomy remains controversial.
Opponents of antireflux procedure argue that a good
postoperative LES pressure with low incidence of
reflux symptoms can be achieved without
fundoplication by avoiding excessive posterior
dissection and limiting the myotomy to 0.5 to 1cm
onto the stomach.
10,49
A recent meta-analysis on 21
studies involving 601 patients concluded that the
rates of GER was not statistically different in patients
who had myotomy with partial fundoplication
compared to those without fundoplication.
50
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Lopushinsky and Urbarch also did not find any
difference in the pattern of antireflux medication use
between patients who had antireflux procedure as
part of a surgical myotomy and those who did not.
38
Therefore, while Heller myotomy and fundoplication
may be safe the need for the antireflux procedure is
unknown. It is generally accepted that a complete
360° wrap Nissen fundoplication should be avoided
because it creates a high pressure zone in the distal
esophagus which negates the intent of the
operation.
50
The commonest antireflux procedure added to
Heller myotomy is the Dor anterior 180°
fundoplication.
14,46,51
This is associated with low rate
of GER as determined by 24-hour pH monitoring.46
Suturing the gastric wall to the edges of the myotomy
according to the Dor technique also maintains the
edges of the myotomy open, thus preventing the
consequences of scar tissue repair and covers any
undetected perforation of the esophageal mucosa
thus preventing any significant postoperative
morbidity.
14,51
Many surgeons consider the Dor
technique an inadequate procedure and instead use
a posterior 270° Toupet fundoplication.
19,22
This




In deciding to treat a patient with BTox injection, PD
or surgical myotomy, there are a number of
considerations including the risk of the procedure, its
relative effectiveness in treating the symptoms of
achalasia and the risk of treatment consequences
such as GER. Several randomized trials have
compared these 3 accepted modalities of treatment
and clarified the best treatment for achalasia. They
all concur that a myotomy or PD are superior to BTox
injection.
2,28,33,52,53
These studies have shown that
BTox and PD are equally effective in the short-term




myotomy and BTox injection also revealed that the
probability of being symptom-free at two years was
87.5% after surgery and 34% after BTox.33 Surgical
myotomy has better long-term control of symptoms
and fewer complications when compared to PD. A
recent population based study reported that both
Heller myotomy and PD provided good relief of
symptom.
38
However, the cumulative risk of
subsequent intervention for achalasia at 10 years was
63.5% for patients initially treated with PD compared
to 37.5% for patients initially treated with surgical
myotomy.
38
Although many studies indicate that
surgical myotomy is superior to PD in providing long
term relief of symptoms, a few physicians still favor
PD because of the relatively higher risk associated
with open surgical myotomy.
33,38,44
However, surgical
myotomy has regained primacy because of the
immense success of laparoscopic Heller myotomy
which is associated with low morbidity, shorter
hospital stay, faster convalescence and less
postoperative pain.
52
When cost analyses were
performed, PD was found to be the most cost-
effective treatment in otherwise healthy
populations.
54
In patients with other co-morbidities
that decrease the life expectancy to less than 2 years,
BTox is more cost-effective.
22,54
Although surgery is
the most effective treatment for achalasia it is the
most costly over the initial period of treatment.
33,54
Dysphagia following cardiomyotomy can be either
persistent or recurrent. Following incomplete
myotomy or the addition of a tight fundoplication,
dysphagia remains practically unaltered soon after
operation or there may be only minor
improvement.
55,56
Dense adhesions and fibrotic
healing at the site of myotomy are the causes of




dysphagia can be treated by endoscopic pneumatic
dilatation or reoperative cardiomyotomy.
57
In
patients with prolonged symptoms the esophagus
may be sigmoid shape which is thought to represent
the most advanced stage of disease. Some surgeons
recommend myotomy as the first line treatment and




esophagectomy as the first-choice treatment
believing that marked esophageal dilatation and
redundancy predict the impossibility of improving
emptying by means of myotomy.
57,58
Furthermore
achalasia is considered to be precancerous with a
reported incidence of 0.2%-2.0%.
59
The chronic
irritation in achalasia leads to squamous hyperplasia
which progress to dysplasia and eventually to
carcinoma.
59
In addition, a p53 protein mutation
study of the esophagus in patients with achalasia
suggests that the entire esophagus may be in a
precancerous state.
60
We believe that every effort at
preserving the native esophagus should be made
before deciding to perform esophagectomy for a
benign disease.
Conclusion
A lot of improvements have been made on the
understanding of the etiology, pathophysiology and
treatment of achalasia in the last two decades.
Although different treatment options are available
definitive cure is lacking. The choice of treatment
involves the consideration of several clinical and
economic factors. On the basis of evidence-based
medicine, laparoscopic Heller’s myotomy is currently
the best treatment and should be considered as the
initial treatment for most patients with achalasia. In
developing countries where facilities are not readily
Achalasia of esophagus: what’s the best treatment? Ahmed A.
Page | 146
available, open surgical myotomy remains an
effective therapeutic option.
Because of the high probability of GER, it is
considered prudent and reasonable to combine the
myotomy with an antireflux procedure, preferentially
a Dor or Toupet fundoplication. Pneumatic dilatation
is an effective form of treatment and appears to be
the most cost-effective alternative but its long-term
efficacy is less than that of surgical myotomy.
Endoscopic BTox injection is safe and effective but
the effect diminishes over time and the need for
multiple repeat injections must be considered. This
may be the optimum treatment in patients with co-
morbidities or those whose life expectancy does not
exceed 2 years. The usefulness of nifedipine and
nitrates is minimal. These drugs should be used only
on temporary basis, while waiting for more effective
therapeutic options. Continued surveillance of
treated patients is necessary because a few of them
may require additional treatment irrespective of the
initial therapeutic modality.
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